Elasmogen is led by industry professionals with broad experience that covers both big Pharma and early-stage biotech. The team has a demonstrated track-record of delivering biologic drugs to the clinic and of securing company exits via trade-sale and IPO.Whilst they share some similarities in terms of their structure and properties with antibodies soloMERs™ are smaller (11 kDa) and more stable proteins, have squeezed a fou...
Elasmogen is led by industry professionals with broad experience that covers both big Pharma and early-stage biotech. The team has a demonstrated track-record of delivering biologic drugs to the clinic and of securing company exits via trade-sale and IPO.Whilst they share some similarities in terms of their structure and properties with antibodies soloMERs™ are smaller (11 kDa) and more stable proteins, have squeezed a fourth binding loop into their single domain format and crucially are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.